ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00498966
Recruitment Status : Completed
First Posted : July 11, 2007
Last Update Posted : February 5, 2018
Sponsor:
Information provided by (Responsible Party):
AEterna Zentaris

Brief Summary:

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are:

  • To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
  • To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor

Condition or disease Intervention/treatment Phase
Kidney Cancer Drug: Perifosine Phase 2

Detailed Description:

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor, while patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Evaluation of each group will be performed separately. The goals of this study are:

  1. To measure clinical benefit defined as an objective tumor response using RESIST or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
  2. To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor.

Treatment Phase/duration of treatment: All patients will be treated with daily perifosine at 100 mg PO daily until tumor progression (by the RECIST criteria) or unacceptable toxicity. Once radiological disease progression has been documented by the treating physician, the patient will go off study. Patients are encouraged to have two measurements for confirmation of progression.

Follow-Up Phase: All patients will be followed-up for SAEs until at least 30 days after discontinuation of perifosine. All patients who are discontinued from perifosine for any reason other than disease progression will continue to have tumor assessments until the patient has documented disease progression or has begun other therapies.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Two groups with regard to pre-treatment: patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor, while patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor.

One treatment group: all patients will receive perifosine 100 mg qhs daily orally. Patients are to be instructed that perifosine is to be taken with food.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Study Start Date : July 2007
Actual Primary Completion Date : July 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Cancer

Arm Intervention/treatment
Experimental: Group A
Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
Drug: Perifosine

Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.

Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food.

Other Names:
  • D-21266
  • KRX-0401

Experimental: Group B
Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
Drug: Perifosine

Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.

Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food.

Other Names:
  • D-21266
  • KRX-0401




Primary Outcome Measures :
  1. Objective tumor response using RESIST OR progression-free survival [ Time Frame: 12 weeks ]
    Clinical benefit, defined as either an objective response by RECIST or PFS >12 weeks, is a primary endpoint of the study. The clinical benefit rate together with its two-sided exact binomial 95% confidence interval will be reported.


Secondary Outcome Measures :
  1. Evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney [ Time Frame: 12 weeks ]
    Safety endpoints include: incidence of adverse events, serious adverse events, change in vital signs and change in laboratory results (hematology, blood chemistry, urinalysis).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with confirmed metastatic RCC
  • Patients must have documented progression on treatment with sunitinib or sorafenib. Prior therapy with bevacizumab and/or cytokines (i.e., IL-2, interferon) is permitted. Prior vaccine therapy in the adjuvant setting is also permitted. Patients can have failed therapy with ONE prior mTOR inhibitor.
  • Patients must have at least one measurable lesion on computer tomography (CT) Scan or magnetic resonance imaging (MRI) using Modified RECIST criteria.
  • Patients must have normal organ and marrow function, unless in the opinion of the treating investigator, the abnormality is related to tumor, and the study chairman agree the abnormality is unlikely to affect the safety of perifosine use. Normal organ and marrow function is described below:

    • ANC >= 1.5 x 109/L
    • Platelets >= 75,000/ mm3
    • HCT >= 28% (with or without growth factor support)
    • Creatinine <= 3.0 mg/dl
    • Total bilirubin <= 1.5 x upper limit of normal
    • Transaminase <= 2.5 x upper limit of normal
  • ECOG performance status of 0 or 1
  • Patients with CNS metastases must be clinically stable for at least 2 months following treatment with radiation therapy, surgery, or both; and be off corticosteroids and anti-seizure medication.
  • Patients with a life expectancy ≥6 months
  • Age ≥18 years old
  • Patients who give a written informed consent obtained according to local guidelines
  • Women of childbearing potential must have had a negative serum or urine pregnancy test 72 hours prior to the administration of the first study treatment.

Exclusion Criteria:

  • Patients who have not recovered (<= grade 1) from adverse events from prior therapy (excluding alopecia).
  • Patients currently receiving sorafenib or sunitinib who have received either of these within 2 weeks prior to study entry.
  • Patients may have had prior sorafenib OR sunitinib BUT cannot have been treated with both VEGF receptor inhibitors.
  • Patients with a known hypersensitivity to perifosine or its excipients.
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.
  • Patients who are using other investigational agents or who had received investigational drugs <= 4 weeks prior to study entry.
  • Patients unwilling to or unable to comply with the protocol.
  • Patients who have a history of another primary malignancy <= 5 years with the exceptions of non melanomatous skin cancer and carcinoma in situ of the cervix.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00498966


Locations
United States, Kentucky
Investigative Site
Louisville, Kentucky, United States, 40202
United States, New Jersey
Investigative Site
Morristown, New Jersey, United States, 07962
United States, New York
Investigative Site
Armonk, New York, United States, 10504
Sponsors and Collaborators
AEterna Zentaris
Investigators
Study Chair: Nicholas J Vogelzang, MD Nevada Cancer Institute

Publications of Results:
Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 5101

Responsible Party: AEterna Zentaris
ClinicalTrials.gov Identifier: NCT00498966     History of Changes
Other Study ID Numbers: Perifosine 231
First Posted: July 11, 2007    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: February 2018

Keywords provided by AEterna Zentaris:
Kidney
perifosine
Progression on treatment with sunitinib or sorafenib

Additional relevant MeSH terms:
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Kidney Diseases
Urologic Diseases